Team:Wageningen UR/Lovastatin
From 2013.igem.org
Line 32: | Line 32: | ||
<html> | <html> | ||
- | <p>As an inhibitor of the enzyme (3-hydroxy-3-methylglutaryl CoA reductase), which plays a significant role in cholesterol biosynthesis, lovastatin is a medicinal compound used against cardiovascular diseases | + | <p>As an inhibitor of the enzyme (3-hydroxy-3-methylglutaryl CoA reductase), which plays a significant role in cholesterol biosynthesis, lovastatin is a medicinal compound used against cardiovascular diseases [<a href="#ref1">1</a>]. It is a naturally occurring drug which is found in food such as oyster mushrooms and red yeast rice. During the production of lovastatin in Aspergillus terreus, toxins could be produced at the same time. However, Aspergillus niger is a mass producer of organic acids with the potential to produce lovastatin more securely. By this project, a more suitable host for lovastatin biosynthesis is likely to be found by cloning and transferring the gene from Aspergillus terreus to the same species fungi Aspergillus niger.</p> |
</html> | </html> | ||
Line 39: | Line 39: | ||
<html> | <html> | ||
<h3>Biosynthesis gene</h3> | <h3>Biosynthesis gene</h3> | ||
- | <p>Lovastatin biosynthesis approach needs the participation of polyketide synthases (PKS), enoyl reductase, esterase and cytochrome P450 oxygenase | + | <p>Lovastatin biosynthesis approach needs the participation of polyketide synthases (PKS), enoyl reductase, esterase and cytochrome P450 oxygenase[<a href="#ref2">2</a>]. Among them, LovB (3038AA), LovG (256AA) [<a href="#ref3">3</a>]. and LovC (363AA) together take charge of most of the production pathway by releasing an intermediate-dihydromonacolin L acid [<a href="#ref3">3</a>] after 35 reactions.</p> |
<p>LovB contains KS (β-ketosynthase), MAT (acyl transferase), DH (dehydratase), MT (methyl transferase), KR | <p>LovB contains KS (β-ketosynthase), MAT (acyl transferase), DH (dehydratase), MT (methyl transferase), KR | ||
(ketoreductase), ACP (acyl carrier protein), CON (nonribosomal-peptide synthase condensation) domains and an | (ketoreductase), ACP (acyl carrier protein), CON (nonribosomal-peptide synthase condensation) domains and an | ||
- | inactive ER domain, which is active in LovC | + | inactive ER domain, which is active in LovC [<a href="#ref2">32</a>][<a href="#ref4">4</a>]. The amino acid sequences |
of LovB and LovC are obtained from analysis of Aspergillus terreus and the functionality of some domains has been | of LovB and LovC are obtained from analysis of Aspergillus terreus and the functionality of some domains has been | ||
- | demonstrated by experiments | + | demonstrated by experiments [<a href="#ref5">5</a>]</p> |
<h3>Domain separation</h3> | <h3>Domain separation</h3> | ||
<p>The minimal polyketide synthase domains of LovB as standalone proteins and assay for their activities and substrate specificities have never been clearly defined or systematically accomplished. With the help of literature,Domcut and BLAST to define the boundaries of each domain,it is able to split enzyme when the structure of separate domains remain functionally. By splitting enzyme into separate domains and expressing them in a vector, it can be possible to rearrange domains from different sources and design an enzyme for the function of particular purposes.</p> | <p>The minimal polyketide synthase domains of LovB as standalone proteins and assay for their activities and substrate specificities have never been clearly defined or systematically accomplished. With the help of literature,Domcut and BLAST to define the boundaries of each domain,it is able to split enzyme when the structure of separate domains remain functionally. By splitting enzyme into separate domains and expressing them in a vector, it can be possible to rearrange domains from different sources and design an enzyme for the function of particular purposes.</p> | ||
Line 56: | Line 56: | ||
<p> | <p> | ||
- | <span id="ref1" class="ref">1.</span> | + | <span id="ref1" class="ref">1.</span>Tobert, J. A. (2003). Lovastatin and beyond: The history of the HMG-CoA reductase inhibitors. Nature Reviews Drug Discovery, 2(7), 517-526.<br/> |
- | <span id="ref2" class="ref">2.</span> | + | <span id="ref2" class="ref">2.</span>Campbell, C. D., & Vederas, J. C. (2010). Biosynthesis of Lovastatin and Related Metabolites Formed by Fungal Iterative PKS Enzymes. Biopolymers, 93(9), 755-763.<br/> |
- | <span id="ref3" class="ref">3.</span> | + | <span id="ref3" class="ref">3.</span>Xu, W., Chooi, Y. H., Choi, J. W., Li, S., Vederas, J. C., Da Silva, N. A., & Tang, Y. (2013). LovG: The Thioesterase Required for DihydromonacolinL Release and Lovastatin Nonaketide Synthase Turnover in Lovastatin Biosynthesis. Angewandte Chemie-International Edition, 52(25), 6472-6475.<br/> |
- | <span id="ref4" class="ref">4.</span> | + | <span id="ref4" class="ref">4.</span>Ames, B. D., Nguyen, C., Bruegger, J., Smith, P., Xu, W., Ma, S., . . . Tsai, S. C. (2012). Crystal structure and biochemical studies of the trans-acting polyketide enoyl reductase LovC from lovastatin biosynthesis. Proceedings of the National Academy of Sciences of the United States of America, 109(28), 11144-11149.<br/> |
- | + | <span id="ref5" class="ref">5.</span>Ma, S. M., & Tang, Y. (2007). Biochemical characterization of the minimal polyketide synthase domains in the lovastatin nonaketide synthase LovB. Febs Journal, 274(11), 2854-2864.<br/> | |
- | <span id=" | + | |
</p> | </p> | ||
</div> | </div> |
Revision as of 09:49, 16 September 2013
- Safety introduction
- General safety
- Fungi-related safety
- Biosafety Regulation
- Safety Improvement Suggestions
- Safety of the Application
Lovastatin
All you need is lov.
Introduction
As an inhibitor of the enzyme (3-hydroxy-3-methylglutaryl CoA reductase), which plays a significant role in cholesterol biosynthesis, lovastatin is a medicinal compound used against cardiovascular diseases [1]. It is a naturally occurring drug which is found in food such as oyster mushrooms and red yeast rice. During the production of lovastatin in Aspergillus terreus, toxins could be produced at the same time. However, Aspergillus niger is a mass producer of organic acids with the potential to produce lovastatin more securely. By this project, a more suitable host for lovastatin biosynthesis is likely to be found by cloning and transferring the gene from Aspergillus terreus to the same species fungi Aspergillus niger.
Strategy and Approach
Biosynthesis gene
Lovastatin biosynthesis approach needs the participation of polyketide synthases (PKS), enoyl reductase, esterase and cytochrome P450 oxygenase[2]. Among them, LovB (3038AA), LovG (256AA) [3]. and LovC (363AA) together take charge of most of the production pathway by releasing an intermediate-dihydromonacolin L acid [3] after 35 reactions.
LovB contains KS (β-ketosynthase), MAT (acyl transferase), DH (dehydratase), MT (methyl transferase), KR (ketoreductase), ACP (acyl carrier protein), CON (nonribosomal-peptide synthase condensation) domains and an inactive ER domain, which is active in LovC [32][4]. The amino acid sequences of LovB and LovC are obtained from analysis of Aspergillus terreus and the functionality of some domains has been demonstrated by experiments [5]
Domain separation
The minimal polyketide synthase domains of LovB as standalone proteins and assay for their activities and substrate specificities have never been clearly defined or systematically accomplished. With the help of literature,Domcut and BLAST to define the boundaries of each domain,it is able to split enzyme when the structure of separate domains remain functionally. By splitting enzyme into separate domains and expressing them in a vector, it can be possible to rearrange domains from different sources and design an enzyme for the function of particular purposes.
gBlocks and Gibson assembly
gBlocks gene fragments, a new tool for synthetic biology were ordered for cloning each domain with the consideration of codon optimization for Aspergillus niger. After the gene was assembled by Gibson assembly in E.coli,it would be isloated and digested before inserting into a vector of A. niger for expression.
Reference
1.Tobert, J. A. (2003). Lovastatin and beyond: The history of the HMG-CoA reductase inhibitors. Nature Reviews Drug Discovery, 2(7), 517-526.
2.Campbell, C. D., & Vederas, J. C. (2010). Biosynthesis of Lovastatin and Related Metabolites Formed by Fungal Iterative PKS Enzymes. Biopolymers, 93(9), 755-763.
3.Xu, W., Chooi, Y. H., Choi, J. W., Li, S., Vederas, J. C., Da Silva, N. A., & Tang, Y. (2013). LovG: The Thioesterase Required for DihydromonacolinL Release and Lovastatin Nonaketide Synthase Turnover in Lovastatin Biosynthesis. Angewandte Chemie-International Edition, 52(25), 6472-6475.
4.Ames, B. D., Nguyen, C., Bruegger, J., Smith, P., Xu, W., Ma, S., . . . Tsai, S. C. (2012). Crystal structure and biochemical studies of the trans-acting polyketide enoyl reductase LovC from lovastatin biosynthesis. Proceedings of the National Academy of Sciences of the United States of America, 109(28), 11144-11149.
5.Ma, S. M., & Tang, Y. (2007). Biochemical characterization of the minimal polyketide synthase domains in the lovastatin nonaketide synthase LovB. Febs Journal, 274(11), 2854-2864.